You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Clinical characteristics of the study population

From: Tryptophan catabolism and immune activation in primary and chronic HIV infection

  Primary HIV infection N = 14 Early presenters N = 24 Late presenters N = 19 Healthy controls N = 16 P
Gender, males/females, (% males) 13/1 (92.9) 22/2 (91.7) 18/1 (94.7) 15/1 (93.8) .948
Age, years, mean (SD) 46 (8.9) 45 (8.2) 47 (10.1) 43 (9.4) .529
CD8+ at baseline, cells/μL, mean (SD) 1238.6 (659.8) 1123.5 (547.5) 820.1 (556.0) 915.7 (409.7) .116
CD4+ at baseline, cells/μL, mean (SD) 577.8 (228.5) a,d 527.9 (111.2)c,f 72.7 (62.7)a,c,e 1144.0 (329.0)d,e,f < .001
CD4/CD8 at baseline, mean (SD) 0.6 (0.4)a,d 0.6 (0.2)c,f 0.1 (0.1)a,c,e 1.4 (0.5)d,e,f < .001
Co-infection with chronic HBV/HCV, N 0/1 1/0 0/2 0/0 NA
HIV RNA at baseline, mean (SD) 2,413,322 (4,119,479)a,b 97,328 (253,967)b,c 486,483 (524,072)a,c NA < .001
AIDS defining events, N 0 0 1 NA NA
KTratio at baseline, mean (SD) 46.8 (20.3)a,b,d 34.8 (10.6)b,c,f 74.5 (48.1)a,c,e 20.9 (3.7)d,e,f < .001
CD8 + CD38 + HLA-DR+, % cells, mean (SD) 44.7 (20.3) a,b,d 22.0 (13.4)b,c,f 25.5 (21.3)a,c,e 1.3 (0.8)d,e,f < .001
CD4 + CD38 + HLA-DR+, % cells, mean (SD) 5.5 (4.1)a,d 3.5 (3.0)c,f 15.5 (15.4)a,c,e 0.8 (0.6)d,e,f < .001
  1. P*: comparing the four groups by using ANOVA if parametric variables or Kruksal-Wallis test if non parametric variables. If significant (<0.05) then t-test if parametric variables or Mann-Whitney if non parametric variables were used to compare two groups. Only significant differences are marked:
  2. aprimary HIV infection vs late presenters
  3. bprimary HIV infection vs early presenters
  4. clate presenters vs early presenters
  5. dhealthy controls vs primary HIV infection
  6. ehealthy controls vs late presenters
  7. fhealthy controls vs early presenters